| Not Yet Recruiting | A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis NCT07502222 | Akeso | Phase 2 |
| Not Yet Recruiting | A Phase II Study of QLS12010 Capsules in Adults With Moderate to Severe Atopic Dermatitis NCT07344051 | Qilu Pharmaceutical Co., Ltd. | Phase 2 |
| Not Yet Recruiting | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy a NCT07465120 | Dermavon Holdings Limited | Phase 2 |
| Not Yet Recruiting | Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Sev NCT07370909 | Shanghai Longwood Biopharmaceuticals Co., Ltd. | Phase 3 |
| Recruiting | A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis NCT07321951 | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 |
| Recruiting | A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatit NCT07211542 | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 |
| Recruiting | Phase 1a/1b Study of TRB-061 in Healthy Participants & Atopic Dermatitis Patients NCT06934252 | TRex Bio, Inc. | Phase 1 |
| Recruiting | Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis NCT06723080 | Jiangsu vcare pharmaceutical technology co., LTD | Phase 3 |
| Active Not Recruiting | Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis NCT06468956 | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 3 |
| Recruiting | Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis. NCT06239311 | medac GmbH | Phase 3 |
| Enrolling By Invitation | A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis NCT06158490 | Guangzhou JOYO Pharma Co., Ltd | Phase 2 |
| Active Not Recruiting | A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Se NCT06136741 | Nektar Therapeutics | Phase 2 |
| Active Not Recruiting | Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic NCT06099704 | Sanofi | — |
| Completed | A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic D NCT06012812 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 2 |
| Terminated | A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD NCT05984784 | Inmagene LLC | Phase 1 / Phase 2 |
| Completed | Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatiti NCT05997927 | Jiangsu vcare pharmaceutical technology co., LTD | Phase 2 |
| Completed | A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCK NCT05899816 | Amgen | Phase 3 |
| Unknown | Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis NCT05702268 | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 2 |
| Completed | Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial NCT05590585 | Regeneron Pharmaceuticals | Phase 4 |
| Withdrawn | Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Respo NCT05056779 | Galderma R&D | Phase 3 |
| Unknown | The Study of CM326 in Moderate-to-severe Atopic Dermatitis NCT05671432 | Keymed Biosciences Co.Ltd | Phase 2 |
| Completed | Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis NCT05549947 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 2 |
| Unknown | The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis NCT05186922 | Keymed Biosciences Co.Ltd | Phase 1 / Phase 2 |
| Completed | Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Derma NCT05203380 | Regeneron Pharmaceuticals | — |
| Unknown | A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS NCT05197023 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China NCT05017480 | Connect Biopharm LLC | Phase 2 |
| Completed | Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis NCT04921345 | Galderma R&D | Phase 2 |
| Completed | The Study of CM310 in Patients With Atopic Dermatitis NCT04893707 | Keymed Biosciences Co.Ltd | Phase 2 |
| Completed | Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD) NCT04805411 | Keymed Biosciences Co.Ltd | Phase 2 |
| Completed | Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD) NCT04893941 | Keymed Biosciences Co.Ltd | Phase 1 / Phase 2 |
| Completed | A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatit NCT04444752 | Connect Biopharm LLC | Phase 2 |
| Active Not Recruiting | Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis NCT03989206 | Galderma R&D | Phase 3 |
| Completed | Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis NCT03989349 | Galderma R&D | Phase 3 |
| Completed | Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis NCT03985943 | Galderma R&D | Phase 3 |
| Completed | Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermati NCT03568162 | Ichnos Sciences SA | Phase 2 |
| Completed | Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Derma NCT03054428 | Regeneron Pharmaceuticals | Phase 3 |
| Recruiting | TREATgermany: German National Clinical Registry for Patients With Moderate-to-severe Atopic Dermatitis NCT03057860 | Technische Universität Dresden | — |
| Completed | Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients NCT02426359 | Qurient Co., Ltd. | Phase 2 |
| Terminated | Dilute Bleach Baths in Pediatric Patients With Atopic Dermatitis NCT01286220 | University of Texas Southwestern Medical Center | N/A |
| Completed | Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis NCT00148746 | Technische Universität Dresden | N/A |